|
|
Article: VICAL/TEVA SIGN SALES/MARKETING PACT FOR ALLOVECTIN IN ISRAEL.
- Article from:
- Worldwide Biotech
- Article date:
- September 1, 2009
CopyrightCOPYRIGHT 2009 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Vical Incorporated (Nasdaq:VICL), San Diego, Calif. has announced an exclusive agreement with Abic Marketing Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., for sales and marketing of the company's Allovectin-7(r) immunotherapeutic product candidate in Israel. Teva has agreed to pay Vical upfront and milestone payments in exchange for the rights to an exclusive license for Israel.
Vijay B. Samant, Vical's President and Chief Executive Officer, said, "We are pleased to collaborate with Teva in serving this key melanoma market, where we are currently enrolling patients at three of Israel's leading clinical centers. As we advance toward completion of ...